Preclinical evaluation of the potential PARP-imaging probe [carbonyl-11C]DPQ
Abstract Background Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for the repair of DNA single-strand breaks and have become key therapeutic targets in homologous recombination-deficient cancers, including prostate cancer. To enable non-invasive monitoring of PARP-1 expression, several PAR...
Saved in:
Main Authors: | Katarína Benčurová, Theresa Balber, Victoria Weissenböck, Lukas Kogler, Joachim Friske, Verena Pichler, Markus Mitterhauser, Marcus Hacker, Cécile Philippe, Marius Ozenil |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-01-01
|
Series: | EJNMMI Radiopharmacy and Chemistry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41181-024-00323-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantitative accuracy of preclinical in ovo PET/MRI: influence of attenuation and quantification methods
by: Theresa Balber, et al.
Published: (2025-01-01) -
Structural modeling of NAD+ binding modes to PARP-1
by: N. V. Ivanisenko, et al.
Published: (2017-02-01) -
PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01) -
PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2025-01-01) -
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)